Plk3 - polo-like kinase 3 Gene

Also Known as Cnk; Fnk

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 58936

About Plk3

Primary_assembly 5: 130,607,142-130,612,317 reverse strand.mRatBN7.2:CM026978.1

This gene has 1 transcript (splice variant), 203 orthologues, 4 paralogues and is associated with 3 phenotypes. Biased expression in Lung (RPKM 39.2), Spleen (RPKM 33.7) and 9 other tissues.

Summary

Predicted to enable p53 binding activity and protein serine/threonine kinase activity. Predicted to be involved in several processes, including Golgi disassembly; intracellular signal transduction; and positive regulation of protein catabolic process. Located in dendrite and neuronal cell body. Orthologous to human PLK3 (polo like kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Plk3 Products (1)

mRNA Protein Name
NM_022187.1 NP_071523.1 serine/threonine-protein kinase PLK3

Gene Ontology

  • Molecular Function
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables protein binding IPI
IPI: Inferred from physical interaction
10523297 RGD
Cellular Component GO Annotation Evidence References Source
located in dendrite IDA
IDA: Inferred from direct assay
10523297 RGD
located in neuronal cell body IDA
IDA: Inferred from direct assay
10523297 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Plk3 Protein Structure

STKc_PLK3

STKc_PLK3: cd14189 (59 - 313)

POLO_box_1

POLO_box_1: cd13118 (460 - 548)

POLO_box_2

POLO_box_2: cd13117 (561 - 628)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 600
  • 647 a.a.
Protein Preferred Names Protein Names

serine/threonine-protein kinase PLK3

  • FGF-inducible kinase

  • PLK-3

  • cytokine inducible kinase

  • cytokine-inducible serine/threonine-protein kinase

  • serine-threonine kinase

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-12137A Volasertib trihydrochloride Inhibitor 99.12% Yes

Clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-12137 Volasertib Inhibitor 99.97% Phase 3
HY-147298 Plogosertib Inhibitor 98.59% Phase 2
HY-15160 TAK-960 Inhibitor 99.75% Phase 1

Pre-clinical Phase

Bioactive Molecules (19)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-10197 Wortmannin Inhibitor 99.86% Unkown
HY-50698 BI 2536 Inhibitor 99.95% Unkown
HY-100789 ON1231320 Inhibitor 99.90% Unkown
HY-11003 GW843682X Inhibitor 99.89% Unkown
HY-12134 Poloxin Inhibitor 98.05% Unkown
HY-108597 TC-S 7005 Inhibitor 99.68% Unkown
HY-15158 SBE13 Hydrochloride Inhibitor 98.56% Unkown
HY-18009 (Z)-LFM-A13 Inhibitor 99.80% Unkown
HY-110002 LFM-A13 Inhibitor 99.65% Unkown
HY-173212 PLK1-IN-13 Inhibitor 98.02% Unkown
HY-149100 PLK1-IN-6 Inhibitor 99.60% Unkown
HY-15160B TAK-960 dihydrochloride Inhibitor 99.15% Unkown
HY-15158A SBE13 Inhibitor / Unkown
HY-172364 PLK1-IN-12 Inhibitor / Unkown
HY-115589 YLT-11 Inhibitor / Unkown
HY-111090 GSK461364 analogue 1 Inhibitor / Unkown
HY-15160A TAK-960 hydrochloride Inhibitor / Unkown
HY-181051 PLK1-IN-16 Inhibitor / Unkown
HY-181030 BDE30671203 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Plk3 NCBI NCBI:1263